Varying safety of add-on second-line T2DM treatments

Varying safety of add-on second-line T2DM treatments

(HealthDay)—For patients with type 2 diabetes who are taking metformin, the risk of cardiovascular events and mortality varies with the addition of different second-line therapies, according to a study published online June 10 in Diabetes, Obesity and Metabolism.

Nils Ekström, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues examined the relative safety of glucose-lowering agents as add-on medication to metformin in type 2 diabetes. Patients on metformin therapy who started another agent were eligible for inclusion; data were obtained for 20,422 patients during the period of 2005 to 2012.

The researchers found that 43, 21, 12, 11, 10, 1, and 1 percent of patients started on second-line treatment with sulfonylurea (SU), , thiazolidinedione (TZD), meglitinide, dipeptidyl peptidase-4 inhibitor (DPP-4i), glucagon-like peptide-1 receptor agonist, and acarbose, respectively. The risk of mortality was higher for basal insulin and lower for TZD compared with SU (hazard ratios, 1.18 and 0.76, respectively). Significantly lower risks of cardiovascular disease, fatal cardiovascular disease, coronary heart disease, fatal , and were seen for DPP-4i.

"This nationwide observational study showed that second-line treatment with TZD and DPP-4i as add-on medication to metformin were associated with significantly lower risks of mortality and compared with SU, whereas basal insulin was associated with a higher risk of mortality," the authors write.

One author is employed by the Swedish Medical Products Agency. Two authors disclosed financial ties to the pharmaceutical industry.


Explore further

CV risk not significantly different for GLP-1 receptor agonists

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Varying safety of add-on second-line T2DM treatments (2016, June 17) retrieved 22 July 2019 from https://medicalxpress.com/news/2016-06-varying-safety-add-on-second-line-t2dm.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more